It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent ...

Eli Lilly has launched Mounjaro in India, a groundbreaking weight loss and diabetes drug, at a fraction of its US price. The ...

More than 500,000 Britons are believed to be using weight loss drugs but a waning appetite is not all they report – there’s also a lack of desire to drink alcohol ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in ...